Webcast: Pills and CEOs Under Fire as M&A Fades

Jul. 09, 2020
1:00 pm - 2:00 pm

Webcast

It is no surprise that activists and the companies they target are shifting gears amid the coronavirus pandemic. In particular, insurgent investors have increased scrutiny on executive pay, operational performance and board alignment at the world’s top companies rather than agitating for M&A or buybacks. Many activist campaigns in 2020 want chief executives out, and they are often ready with candidates to fill the position. But companies aren’t standing by as their valuations dip and they become susceptible to activists or hostile bids. To defend themselves, corporations have installed poison pills of all shapes and sizes and sold large chunks of shares or debt to private investors to secure their positions and the viability of their companies. How effective has the 2020 wave of shareholder rights plans been in defending companies from activists? What other strategies are companies employing to defend themselves amid the pandemic and how are activists approaching campaigns during one of the biggest economic disruptions of the last century?

While the live webcast is over, you can still watch the video replay by clicking here.

Speakers

Christopher Kiper
Co-Founder & Managing Director, Legion Partners

Christopher Kiper is the Co-Founder & Managing Director of Legion Partners.

Read Bio
Ken Bertsch
Executive Director, Council of Institutional Investors
Read Bio
Ben Rosenzweig
Partner, Privet Fund
Read Bio
Martin L. Seidel
Partner, Willkie Farr & Gallagher LLP
Read Bio
MODERATOR: Ronald Orol
Senior Editor, The Deal
Read Bio

Sponsors

Contact Us

Fill out the form to reach our team regarding your inquiries related to Registration, Sales/Sponsorship, Speaking, and Press. You can also subscribe to the Events Newsletter to keep up-to-date with The Deal Events.

More Upcoming Events

Sep
21
The Deal Economy

The Deal Economy: Predictions and Perspectives

The Deal Economy virtual event features a week of online sessions covering the state of the M&A market as it rebounds from the Covid-19 pandemic and heads into 2021.